Table 2.
Clinical features of the 152 epithelial ovarian cancer (EOC) patients involved grouped by training set and validation set.
| Variables | Total (n = 152) | Training group (n = 114) | Validated group (n = 38) | p-value |
|---|---|---|---|---|
| CTC counts (n/5 mL) | 8.70 ± 5.69 | 8.64 ± 5.38 | 8.72 ± 4.65 | 0.935 |
| M-CTC (n %) | 0.24 ± 0.19 | 0.25 ± 0.21 | 0.22 ± 0.14 | 0.413 |
| E-CTC (n %) | 0.57 ± 0.25 | 0.56 ± 0.17 | 0.59 ± 0.23 | 0.392 |
| Hybrids-CTC (n %) | 0.19 ± 0.11 | 0.21 ± 0.18 | 0.20 ± 0.14 | 0.755 |
| Neutrophil (109/L) | 5.22 ± 2.91 | 4.67 ± 2.83 | 5.31 ± 1.96 | 0.198 |
| lymphocyte (109/L) | 1.42 ± 0.63 | 1.46 ± 0.85 | 1.37 ± 0.77 | 0.564 |
| Platelet (109/L) | 320.39 ± 78.68 | 299 ± 73.94 | 314 ± 80.21 | 0.291 |
| Albumin (g/L) | 40.49 ± 6.58 | 38.27 ± 9.38 | 41.22 ± 10.02 | 0.101 |
| CA-125 (U/mL) | 990.71 ± 365.41 | 1001.23 ± 330.98 | 986.53 ± 310.27 | 0.810 |
| CA-199 (U/mL) | 129.03 ± 53.18 | 121.88 ± 48.27 | 132.5 ± 59.12 | 0.270 |
| AFP (ng/mL) | 6.21 ± 4.78 | 6.43 ± 5.99 | 5.93 ± 3.45 | 0.627 |
| CEA (ng/mL) | 3.02 ± 2.57 | 2.95 ± 2.60 | 3.21 ± 2.47 | 0.589 |
| HE4 (pmol/L) | 536.12 ± 54.48 | 542.32 ± 79.39 | 521.39 ± 62.10 | 0.141 |
CTC circulating tumor cell, M-CTC mesenchymal CTCs/ total CTCs percentage, E-CTC epithelial CTCs/ total CTCs percentage, Hybrids-CTC hybrids CTCs/ total CTCs percentage, CA-125 carbohydrate antigen-125, CA-199 carbohydrate antigen-199, CEA carcinoembryonic antigen, AFP alpha-fetoprotein, HE4 human epididymis protein 4.